Fig. 5: nOPV2-c1. Frequency of variants in EES at known attenuation sites and mTgmNVT results. | npj Vaccines

Fig. 5: nOPV2-c1. Frequency of variants in EES at known attenuation sites and mTgmNVT results.

From: Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses

Fig. 5: nOPV2-c1. Frequency of variants in EES at known attenuation sites and mTgmNVT results.

Participant vaccination history is IPV only. EES day shown with mTgmNVT result (red colour gradient) and variant frequency (blue colour gradient) averaged across two stool replicates (SS) and culture-amplified virus (I), if present. Amino acid associated with variant indicated, if applicable. S = Stool replicate; I = Culture-amplified virus isolate (SSI = Two stool replicates and culture-amplified virus isolate; SI = Single stool replicate and isolate). White cells = variant not detected. Grey cells = mTgmNVT result not available or no NGS data from stool (S)/culture-amplified virus (I). The NGS pipeline reports the variants as SNPs. Coding impact assumes changes are not in common genomes when multiple variants are observed in VP1-143. a M4a phase 1 trial nOPV2-c1 cohort. b M4 phase 2 trial nOPV2-c1 cohort. All variants reported have Q scores ≥ 30.

Back to article page